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Abstract: Chronic obstructive pulmonary disease (COPD), one of the most common chronic 
diseases and a leading cause of death, has historically been considered a disease of men. However, 
there has been a rapid increase in the prevalence, morbidity, and mortality of COPD in women 
over the last two decades. This has largely been attributed to historical increases in tobacco 
consumption among women. But the influence of sex on COPD is complex and involves several 
other factors, including differential susceptibility to the effects of tobacco, anatomic, hormonal, 
and behavioral differences, and differential response to therapy. Interestingly, nonsmokers with 
COPD are more likely to be women. In addition, women with COPD are more likely to have a 
chronic bronchitis phenotype, suffer from less cardiovascular comorbidity, have more concomi-
tant depression and osteoporosis, and have a better outcome with acute exacerbations. Women 
historically have had lower mortality with COPD, but this is changing as well. There are also 
differences in how men and women respond to different therapies. Despite the changing face 
of COPD, care providers continue to harbor a sex bias, leading to underdiagnosis and delayed 
diagnosis of COPD in women. In this review, we present the current knowledge on the influence 
of sex on COPD risk factors, epidemiology, diagnosis, comorbidities, treatment, and outcomes, 
and how this knowledge may be applied to improve clinical practices and advance research.
Keywords: chronic obstructive lung disease, sex, smoking, comorbidity, sex bias
Introduction
Chronic obstructive pulmonary disease (COPD) is one of the most common chronic 
conditions worldwide, and is now the third-leading cause of death in the US.1 Over 
the past 20 years, COPD-related measures, including prevalence and mortality, have 
increased more rapidly among women than among men, altering the historical percep-
tion that COPD is predominantly a disease of men.2 These changes have historically 
been attributed to the changes in smoking over the last century. Recent evidence sug-
gests that men and women differ in their susceptibility to COPD risk factors,3 possibly 
related to biologic and hormonal mechanisms. In addition, the clinical presentation of 
COPD, comorbidities, and other factors vary between sexes and may influence response 
to treatment. We summarize data on how sex influences risk factors, epidemiology, 
clinical presentation, treatment, and outcomes of COPD, and how this knowledge may 
help us develop better management strategies.
Sex differences in risk factors of COPD
Table 1 is a summary of the differences seen in COPD-related risk factors between 
men and women.
International Journal of COPD 2014:9submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1146
Aryal et al
Table 1 Summary of the influence of sex on COPD risk factors
Risk factors Male Female
Tobacco use – Tobacco use peaked in the 1970s in the US among men4 –  Tobacco use peaked in the 1980s in the US, and continues  
to increase in the developing world4,5
–  Women may be more susceptible to tobacco smoking  
and develop COPD earlier and with lesser exposure6
Occupational  
exposures
–  Organic dusts from agriculture, mining (coal, heavy  
metals), and other industries (metallic fumes like cadmium  
and aluminum)14
–  women now working in traditionally male occupations
–  Traditionally more exposed to textiles, brassware, ceramics, 
and glassware, especially in the developing world14
Nonoccupational 
exposures
–  Air pollution is increasing in the developing world,  
especially India and the People’s Republic of China,  
and affects men more due to their mobility  
and job types (eg, cab driver)
–  Air pollution will be more of a concern as women assume 
more male-held jobs; indoor air pollution is a major concern  
in the developing world16
Asthma –  Asthma is an important comorbidity and risk factor for 
COPD17
–  Asthmatic women are more susceptible to COPD, and have 
poorer quality of life and utilize more health care18
Genetic factors –  Genetics plays an important role in development of COPD –  Genetically predisposed to develop severe early onset COPD20
Infections –  Infections are important factors for AeCOPD  
and progression of disease
–  Develop lower respiratory infections more frequently  
than women22
–  Upper respiratory infections more common than in men22
Abbreviation: AECOPD, acute exacerbations of chronic obstructive pulmonary disease.
Smoking
Cigarette smoking is the most important risk factor for 
COPD in the developed world. COPD related to tobacco 
consumption increased over the past 100 years in most of 
the developed world as large numbers of men, then women, 
took up smoking. In the US, cigarette smoking peaked during 
the 1970s among men and during the 1980s among women. 
In the developing world, the prevalence of smoking among 
women is predicted to increase to 20% by 2025.5 Future 
trends in COPD will reflect this change.
Men and women may have differential susceptibility 
to tobacco smoke. Women develop more severe COPD at 
younger ages than men and with lower levels of cigarette 
exposure.6 In the NETT (National Emphysema Treatment 
Trial) study, women had fewer pack-years of cigarette 
smoking than men, but had similarly severe COPD.7 A 2006 
meta-analysis of smoking and COPD by Gan et al found 
that female smokers had a faster annual decline in forced 
expiratory volume in 1 second (FEV
1
) than male smokers.8 
Moreover, Sørheim et al observed that among people with 
COPD younger than age 60 years, women had a lower mean 
FEV
1
 and more severe COPD with less cigarette-smoking 
exposure.9 In that study, women had greater reductions in 
FEV
1
 than men when they had fewer than 20 pack-years 
of exposure, but after 25 pack-years of smoking, the dose–
response relationship of men and women was similar.
The heightened susceptibility to cigarette smoke in 
women could have several etiologies. First, there may be 
a genetic predisposition for smoking-related lung  damage 
in certain families that is sex-specific. Silverman et al 
found a very high prevalence of COPD among women 
(71.4%) in a study of 84 probands with severe early onset 
COPD. In  addition, smoking female first-degree relatives of 
these probands were nearly twice as likely to have airway 
obstruction and 3.5 times as likely to have severe obstruc-
tion than smoking male relatives.10 Second, women may 
have an increased dose-dependent tobacco susceptibility. 
Women have smaller lungs and airways than men;  therefore, 
the same amount of tobacco smoke results in greater 
 exposure. Furthermore, exposure to secondhand smoke and 
male/female differences in cigarette-brand preference and 
inhalational techniques may also be a factor.11 Third, there 
may be hormonally mediated differences in tobacco-smoke 
metabolism. For example, animal studies demonstrate that 
cytochrome P450 enzymes are upregulated by estradiol, 
potentially making female lungs more susceptible to ciga-
rette  smoke-related oxidant.12
Occupational exposure
Chronic exposure to occupational dusts is a risk factor for 
the spectrum of chronic respiratory diseases.13 Common 
occupational exposures linked to COPD include those that 
come from mining (coal, heavy metals), agriculture (organic 
dusts), and other industries (metallic fumes like cadmium and 
aluminum).14 These occupations have classically been held 
by men. However, with the reassignment of sex roles and 
more single-parent families, a higher number of women are 
filling those historically male-held jobs. In addition, women, 
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especially in the developing world, are working in other 
dusty industries like the production of textiles, brassware, 
ceramics, and glassware.
Nonoccupational exposure
Although air-pollution levels have been decreasing in many 
parts of the world, these levels remain elevated in some 
countries like the People’s Republic of China and India. 
This is of particular significance, as recent data suggest that 
girls experience more reduction in pulmonary function than 
boys when they have exposure to either environmental air 
pollution or tobacco smoke.15
In addition, indoor air pollution disproportionately affects 
women, particularly in the developing world. This is primar-
ily due to the common practice of using unprocessed solid 
fuels, such as wood and dung, for cooking and heating and 
the reality that cooking is often a task done exclusively by 
women.16
Asthma
Asthma is a common comorbidity, as well as a risk factor for 
COPD. People with asthma are at much higher risk of having 
COPD.17 A longitudinal study by Silva et al found that com-
pared to nonasthmatics, active asthmatics had a tenfold-higher 
risk for acquiring symptoms of chronic bronchitis, a 17-fold 
higher risk of receiving a diagnosis of emphysema, and a 
12-fold higher risk of having COPD, even after adjusting for 
smoking history and other potential confounders.18
The influence of sex on asthma has been studied 
extensively. Studies show an increased incidence and preva-
lence of asthma in women, and that asthmatic women have a 
lower quality of life (QoL) and more utilization of health care 
compared to their male counterparts, despite similar medical 
treatment and lung function.19 Researchers continue to study 
the reasons for these differences, including the potential affect 
of sex hormones, differential perception of airflow obstruc-
tion, atopy, heightened bronchial hyperresponsiveness, and 
medication compliance and technique. The relationship is 
likely a complex one involving all those factors.
Genetics
Genetics plays an important role in the development of 
COPD. The most well-known genetic factor in the develop-
ment of COPD is the deficiency of the enzyme α
1
-antitrypsin. 
However, there are a number of other genes that are likely 
involved in the pathogenesis of COPD. Foreman et al ana-
lyzed data from 2,500 subjects in the COPDGene study, 
a large study that enrolled smokers with and without COPD 
at 21 clinical centers throughout the US.20 Severe, early onset 
COPD participants were overwhelmingly female (66%), 
with higher rates among African American smokers. The 
 COPDGene study has a longitudinal component that will pro-
vide new insights into the biologic and sex differences in the 
genetic predictors of COPD development and progression.
Infections
Bacterial and viral infections are a major cause of acute 
exacerbations of COPD, and contribute to the development 
and progression of COPD.21 Sex may influence the develop-
ment and outcomes of upper and lower respiratory infections, 
although this has not been studied extensively. An analysis 
of 84 published studies demonstrated that upper respira-
tory infections were more common in women, while lower 
respiratory infections were more common in men.22 The 
same analysis demonstrated that the course of most respira-
tory infections is more severe in males, leading to higher 
mortality, especially with community-acquired pneumonia. 
Similar findings have been reported in other studies, as noted 
in the outcome sections to follow. The precise reasons behind 
these differences are not clear, although biologically and 
hormonally mediated variability in immunity and behavioral 
differences may be involved.
Sex differences in the  
prevalence of COPD
Sex influences COPD in a number of different ways. Table 2 
is a summary of these differences in prevalence, comorbidi-
ties, and response to different treatment modalities. The mea-
surement and monitoring of the burden of COPD, despite its 
high prevalence, remains difficult. Prevalence estimates of 
COPD rely on a number of measures, including self-report, 
administrative databases, and lung-function testing. In 
 general, higher prevalence is seen among men with analyses 
of administrative databases, while self-reports show higher 
prevalence among women.23
In the US, between the first and third National Health and 
Nutrition Examination Surveys (NHANES), the prevalence of 
spirometrically determined COPD increased among women 
from 50.8 to 58.2 per 1,000, while the prevalence decreased 
among men from 108.1 to 74.3 per 1,000.24 Findings from 
the National Health Interview Survey (NHIS) show that the 
self-reported prevalence of COPD (chronic bronchitis and 
emphysema) in the US did not change between 1998 and 
2009, and has remained higher among women than among 
men (Figure 1).25 Similar patterns have been observed in other 
developed countries like Canada,  Netherlands, and Austria.26–28 
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Figure 1 Prevalence of self-reported chronic obstructive pulmonary disease among 
adults aged 18 and over: US, 1998–2009.
Note: Data from Akinbami LJ, Liu X. Chronic obstructive pulmonary disease among 
adults aged 18 and over in the United States, 1998–2009. 2011. Available from: 
http://www.cdc.gov/nchs/data/databriefs/db63.htm.25
Table 2 Summary of the influence of sex on the prevalence, diagnosis, and outcomes of chronic obstructive pulmonary 
disease (COPD)
Outcomes Male Female
Prevalence –  Historically more prevalent in males by administrative  
database analysis23
–  Prevalence decreasing in the US,24 but still rising  
in developing countries
–  Mostly emphysematous phenotype33,34
–  Prevalence is higher by self-report,23,25 and is 
increasing in females24
–  Mostly chronic bronchitis phenotype 
In the US, the number of women diagnosed annually 
with emphysema now surpasses that of men as of 
201134
Quality of life –  Poor quality of life compared to general population –  Poorer quality of life than men and more intense 
dyspnea40,44,46
Diagnosis –  More likely to be diagnosed with COPD50,51
–  Fewer reports of diagnostic delay or reaching physician
–  More likely to be diagnosed with asthma50,51
–  More diagnostic delay, difficulty reaching physician,  
or having adequate time52
Comorbidities –  IHD, arrhythmias, alcoholism, renal failure, cancers  
more common45,53,54
–  Depression, anxiety, osteoporosis, reflux, IBD more  
common45,53–57
Acute exacerbations  
and hospitalizations
–  Mortality higher after exacerbation, higher average  
number of hospitalizations per year42,75–77
–  Mortality may be lower after exacerbation42,75–77
Responses  
to treatment options
–  More attempts at and more sustained quitting  
of smoking; nicotine replacement more effective32,59,60
–  ICS reduces phlegm more63
–  Benefits of LTOT may not be as good as in women
–  Effects of pulmonary rehabilitation may be more  
sustained72
–  Fewer quit attempts, less sustained quitting, but  
better improvement in FEV1 with quitting
32,59,60
–  ICS may not reduce phlegm as well.63 but 
deterioration may be worse on stopping;65 chronic  
macrolide therapy may be more effective66
–  More emotional and psychosocial benefits  
from pulmonary rehabilitation73
Mortality –  Declining over last few decades23 –  Increasing over last few decades; and predicted to  
continue to rise;23 more women have died than  
men from COPD in the US since 200023
Abbreviations: IHD, ischemic heart disease; IBD, inflammatory bowel disease; FEV1, forced expiratory volume in 1 second; ICS, inhaled corticosteroids; LTOT, long-term 
oxygen therapy.
In the developing world, diagnosed COPD remains higher 
among men than among women;29–31 while some of these differ-
ences may reflect a sex bias in the diagnosis of COPD, the future 
will likely see increasing prevalence among women as more take 
up smoking and work in traditionally male occupations.32
Sex differences in the  
expression of COPD
There are also phenotypic differences between women and 
men in the expression of COPD, which might help explain 
some of the prevalence differences noted earlier. In 1987, 
Burrows et al suggested that sex dimorphism may be pres-
ent in COPD when they described two types of COPD: 
emphysema and chronic asthmatic bronchitis.33 People with 
emphysema were more likely to be men, experienced more 
rapid decline in pulmonary function, and had a higher mor-
tality rate. People with chronic asthmatic bronchitis were 
more likely to be women, experienced less rapid decline in 
pulmonary function, and had a lower mortality rate. NHIS 
data similarly suggest that chronic bronchitis is more com-
mon among women, and emphysema is traditionally more 
common among men, although since 2011 more women in 
the US have been diagnosed with emphysema than men.34 
Radiologic and histologic data also show similar findings, 
with women having less severe emphysema but thicker 
airway walls and smaller airway lumens.35
An interesting observation with regard to sex is seen 
in COPD among never-smokers. About 15%–30% of all 
people who have evidence of COPD are never-smokers. Of 
this group, nearly 80% are women, suggesting that women 
may be more susceptible to nonsmoking-related factors.36 
In one prospective study of COPD among never-smokers, 
sputum eosinophilia was elevated in one group and sputum 
neutrophil count was elevated in another.37 The group with 
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the neutrophilia had a higher prevalence of organ-specific 
autoimmune disease and autoantibodies, including thyroid 
disease. In another study, changes in the bronchoalveolar 
lavage-cell proteome were found in female but not male 
patients.38 These observations suggest that increased respon-
siveness of the female immune system may be responsible 
for some sex-related differences.39
Women who have COPD are more likely to report 
dyspnea40,41 and less likely to report the production of 
phlegm.40,42 In addition, women report higher intensity of 
dyspnea despite fewer pack-years of smoking and similar 
degrees of pulmonary impairment.41 A recent Spanish 
study showed that women reported less phlegm than men 
but a similar level of cough, dyspnea, and wheezing.43 An 
analysis of the PLATINO (Proyecto Latinoamericano de 
Investigación en Obstrucción Pulmonar) cohort showed 
that dyspnea was more common among women both with 
and without COPD.44 In the ECLIPSE (Evaluation of COPD 
Longitudinally to Identify Predictive Surrogate Endpoints) 
cohort, when stratified by COPD-severity category, men 
and women had a similar age, but women had less smoking 
exposure, lower body mass index and fat-free mass index, 
and more exacerbations than men.45 In the TORCH (Towards 
a Revolution for COPD Health) study, women reported 
more exacerbations and worse dyspnea.46 The Euroscop 
study demonstrated that FEV
1
 as well as change over time 
correlated with prevalence, remission, and incidence of 
symptoms in men. This study suggests that symptoms are a 
good predictor of disease status and/or underlying disease 
activity, particularly among men.47
The reasons behind differences in clinical expression of 
COPD between men and women are likely multifactorial. 
Becklake and Kauffmann suggested that societal concepts of 
athleticism may cause men to report less breathlessness than 
women;48 others have suggested that sociocultural factors 
may result in women being less likely to report the production 
of sputum or phlegm.23 Some physiologic data suggest that 
fat-free body mass, which is lower in women with COPD, is 
related to a lower diffusion capacity and more dyspnea.49
Sex bias in the diagnosis of COPD
Health care providers are more likely to diagnose COPD 
in men than women. This has important implications in the 
care and outcome of these patients. Two studies assessed sex 
bias in the diagnosis of COPD among health care workers 
in recent years. In 2001 in the US and Canada, Chapman 
et al had a study published50 that was replicated in Spain by 
Miravitlles et al in 2006.51 The Confronting COPD Survey 
also found that after adjusting for age, pack-years, country, 
and dyspnea scores, women were less likely to have had 
spirometry but more likely to have had smoking-cessation 
advice.40 In another recent study of more than 3,500 patients 
by Ancochea et al, 73% of patients with spirometric COPD 
criteria were underdiagnosed clinically, and this percentage 
varied by sex, being 30% more frequent among women 
(86.0%) than among men (67.6%).43 Also, a study looking 
at the perception of COPD found that women were more 
likely to report COPD diagnostic delay, difficulty reaching 
the physician, and not being able to spend sufficient time with 
the physician.52 Together, these data suggest that women with 
COPD are underdiagnosed and less likely to be controlled 
and content with their COPD treatment.
Sex differences in comorbidities
Patients with COPD often have coexisting medical condi-
tions that contribute to morbidity and mortality. Although 
sex differences in comorbidities are relatively understudied, 
men and women differ in their patterns of comorbid diseases, 
which might explain, in part, the differences in outcomes 
between the two sexes. In the ECLIPSE cohort, cardiovascular 
comorbidity and diabetes were less common among women, 
whereas osteoporosis, inflammatory bowel disease, reflux, 
and depression requiring treatment were more common.45 
In a European study, women with COPD had less ischemic 
heart disease and alcoholism, but more chronic heart failure, 
osteoporosis, and diabetes mellitus.53 A recent Swedish study 
of oxygen-dependent COPD patients showed that men had 
more arrhythmia, ischemic heart disease, cancer and renal 
failure, fewer mental disorders, and less osteoporosis, hyper-
tension, and rheumatoid arthritis than women.54 Women also 
had more anxiety and depression and worse symptom-related 
QoL than men.55,56 Symptoms and QoL measures may be more 
important determinants of depression in women with COPD 
than physiologic and biologic measures.57
Sex-related differences in  
treatment options for COPD
Smoking cessation
Smoking cessation is the only intervention documented 
to slow lung-function decline.58 Women are not only more 
susceptible to adverse effects of tobacco smoking but also 
they may have more benefits upon successfully quitting 
smoking. This was demonstrated in the Lung Health Study 
that showed that women who remained nonsmokers had an 
average improvement in their FEV
1 
% predicted during the 
first year that was 2.5 times greater than the improvement 
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seen in their male counterparts.59 However, women may 
have more difficulty quitting and have a lower long-term 
success rate of smoking cessation than men do; this may be, 
in part, due to less symptomatic benefit upon quitting among 
women.32 Recent population data from the US, Canada and 
the UK suggest similar rates of successful tobacco cessation 
between sexes.60 Older pharmacologic therapy with nicotine 
replacement was more beneficial among men, whereas the 
newer agents bupropion and varenicline seem to be equally 
effective in women and men.32
Pharmacologic management of COPD
There are few data on sex differences in different therapies for 
COPD, because most studies of pharmacologic agents have 
not been designed to assess treatment in men versus women 
and most trials have enrolled more males than females.3 
For example, little is known about how differences in lung 
anatomy and physiology of males and females may affect 
dosage, delivery, and effectiveness of inhaled medications. 
Based on current studies, there is minimal known effect of sex 
on efficacy and adverse events of current agents. One study 
found no male/female differences in the efficacy of salmeterol/
fluticasone combination therapy on predose FEV
1
, exacerba-
tion rate, or QoL scores.61 Another study demonstrated that the 
effects of tiotropium on lung function, symptoms, and QoL 
were similar in men and women.62 Budesonide led to a reduc-
tion in phlegm among men but not women in the Euroscop 
study.63,64 The probability of respiratory deterioration (either 
symptomatic or exacerbations) when stopping inhaled steroids 
is higher among women than among men.65 In a recent study 
of azithromycin for the prevention of acute exacerbations of 
COPD, a subgroup analysis showed a nonstatistical differ-
ence favoring women.66 Large and better-designed trials are 
necessary to determine whether clinically meaningful sex 
differences exist in the pharmacotherapy of COPD.
There may also be sex differences in prescribing habits of 
providers, as well as compliance with medications between 
men and women. Dales et al found that among patients 
with mild-to-moderate COPD, the proportion of females on 
respiratory medications was twice that of males; this dif-
ference was not seen in severe COPD.67 On the other hand, 
Sestini et al found that men with COPD were more likely 
than women to be on the “new” dry-powder inhalers versus 
metered-dose inhalers.68
Long-term oxygen therapy
Long-term oxygen therapy (LTOT) improves survival among 
hypoxemic patients with COPD, but the impact of sex on 
LTOT has been mixed. A meta-analysis of LTOT showed 
that women on LTOT had a survival advantage over men.69 
However, Machado et al reported that in a cohort of patients 
with COPD receiving LTOT, survival was significantly 
worse among women.70 Discrepancies between these studies 
may be due to patient population and analytical approaches, 
and the criteria for indications to start LTOT.
vaccination
Studies on sex differences in vaccination are scant. One 
study from Israel showed that women were less likely to 
receive influenza and pneumococcal vaccinations,71 but it 
is not clear that this finding can be extrapolated to other 
countries and cultures.
Pulmonary rehabilitation
A multidisciplinary pulmonary rehabilitation program 
should be part of the therapy of all patients with COPD, and 
should include components of exercise training, nutritional 
 counseling, and patient education. Foy et al demonstrated 
that after 3 months of exercise therapy, both men and 
women reported similar improvements in health-related QoL 
(HRQoL) measures; after 18 months, however, continued 
benefits were seen in men but not in women.72 Haggerty et al 
assessed improvements in outcomes among 164 subjects 
(54% female) in pulmonary rehabilitation.73 They found 
that women experienced larger improvements in the mastery 
and emotion subscales of the Chronic Respiratory Disease 
Questionnaire (CRDQ) and the psychosocial subscale of 
the Pulmonary Function Status Scale (PFSS); however, 
all other outcomes (other subscales of the CRDQ and the 
PFSS, and 6-minute walk distance) were similar between 
men and women.
Influence of sex in  
outcomes of COPD
Differences in morbidity, acute 
exacerbations, and hospitalizations
COPD is a major source of morbidity globally. The differ-
ence in prevalence of COPD, diagnosis, comorbidities, and 
outcomes with treatment in the two sexes has been discussed 
in the prior sections. Females also have a decreased HRQoL 
related to COPD. In both the PLATINO and TORCH cohorts, 
more females identified their health as fair to poor compared 
to males, and currently smoking females had more severe 
disease than males.44,46 In addition, the factors determining 
HRQoL for men and women with COPD may differ by sex. 
In one study among men, the total SGRQ score was predicted 
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Figure 2 Changes in rates of death from chronic obstructive pulmonary disease over time among current female and male smokers in three time periods.
Note: Reproduced from N Engl J Med, Thun MJ, Carter BD, Feskanich D, et al. 50-year trends in smoking-related mortality in the United States. 2013;368:351–364. Copyright 
©2013 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.80
by dyspnea, exercise capacity, degree of hyperinflation, and 
comorbidity, whereas among women the only predictors 
were dyspnea and oxygenation status.74
Men and women differ in the outcomes of acute exacer-
bations and hospitalizations of COPD, with women gener-
ally having a survival advantage. In one study of COPD 
exacerbations in the emergency department, Cydulka et al 
found higher relapse rates among men despite similar levels 
of care provided in the hospital.42 However, they also found 
that women were less likely to self-medicate with anticho-
linergic agents, and were less likely to seek emergency care 
within the first 24 hours of exacerbation. Cao et al found 
among 186 patients with COPD in Singapore that men had 
more hospital admissions in a year for COPD exacerbations 
than women.75 In a recent analysis of over 40,000 people in 
Canada, Gonzalez et al found that men had an increased risk 
of death and hospitalization for COPD.76 Patil and colleagues 
also found an increased risk for in-hospital mortality among 
men admitted for an acute exacerbation of COPD.77
Differences in mortality
Between 1990 and 2010, COPD became the third-leading 
cause of death in the US. Death rates for COPD declined 
among US men between 1999 (57.0 per 100,000) and 
2006 (46.4 per 100,000), whereas there was no significant 
change in death rates among women (35.3 per 100,000 in 
1999 and 34.2 per 100,000 in 2006). In 2000, the absolute 
number of women dying from COPD surpassed the num-
ber of men, although the age-adjusted COPD death rates 
for men were 30% higher than those rates for women.23 
In 2009, de Torres et al showed that after controlling for 
disease severity, women had significantly better survival 
than men.78
A recent assessment of changes in mortality rates due 
to COPD in the cohorts from NHANES I and NHANES III 
in the US showed a smaller decrease in the mortality rate 
among women with moderate or severe COPD than among 
men (3.0% versus 17.8%).79 An analysis of smoking-
related mortality in the US evaluated temporal trends in 
sex-specific smoking-related mortality across three time 
periods (1959–1965, 1982–1988, 2000–2010) in seven large 
cohorts.80 In the “contemporary” cohort (2000–2010), male 
and female current smokers had similar relative risks for 
mortality from COPD (26.61 for men, 22.35 for women), 
with these relative risks representing almost a doubling of 
risk compared to the 1982–1988 time period (Figure 2). The 
survival advantage that women with COPD have historically 
had has been slowly diminishing in recent years. Finally, in 
a recent analysis of the BOLD (Burden of Obstructive Lung 
Disease) cohort, spirometric restriction was more predic-
tive of increased mortality risk than airflow obstruction in 
both the sexes, with worse mortality seen in lower-income 
groups.81
Conclusion
The influence of sex on COPD risk and outcomes is due 
to a combination of both environmental/behavioral factors 
and genetic/biophysiologic factors. In addition, the roles 
that women play in society, along with cultural norms and 
expectations, are changing rapidly in both the developed and 
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developing worlds. Identifying the reasons and  mechanisms 
behind those factors, as well as the sex differences in the 
pattern of comorbidities, exacerbations, and therapeutic 
response, may lead to improved therapies and outcomes.
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